PUMA BIOTECHNOLOGY, INC.
Company Stats
- Market Cap
- $512.6M
- as of Sep 30, 2026
- Enterprise Value
- $585.0M
- Shares Outstanding
- 51.6M
- Free Float
- 80.9%
Income Statement
- Revenue
- $228.4M
- Operating Income
- $37.3M
- Net Income
- $31.1M
- EBITDA
- $37.7M
- Revenue Growth, 3Y
- 0.0%
- FCF Margin, 3Y Avg
- 15.5%
- FCF Margin, Worst Year
- 11.4%
Cash Flow
- Free Cash Flow
- $41.7M
- FCF Yield
- 8.1%
- Owner FCF Yield
- 6.8%
Balance Sheet
- Cash & Equivalents
- $29.6M
- Total Debt
- $102.0M
- Net Debt
- $72.4M
- Net Debt / EBITDA
- 1.92x
- EV / EBITDA
- 15.52x
- Net Debt / EBIT
- 1.94x
Returns & Capital
- SBC, 3Y Avg
- $8.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $228.4M | $41.7M | 18.3% |
| FY2024 | $230.5M | $38.9M | 16.9% |
| FY2023 | $235.6M | $26.9M | 11.4% |
| FY2022 | $228.0M | -$15.8M | -6.9% |
| FY2021 | $253.2M | $20.6M | 8.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges